Öйú¼ÓÈëICH,ÕæÕýÈÚÈë¹ú¼ÊÒ©Æ·¼à¶½ÌåϵµÄ¿ªÊ¼

²Î¿¼ÎÄÏ×:

£Û1£ÝÓÚÀö.͸ÊÓÏÖ×´×ÅÑÛδÀ´¡ª¡ª¡¶ÖйúÒ©ÎïÁÙ´²ÊÔÑéÏÖ×´ºÍ·¢Õ¹¡·µ÷Ñб¨¸æÕýʽ·¢²¼£ÛJ£Ý.Öйú´¦·½Ò©,2009(12) : 22-24£®

£Û2£Ý Verma K.Base of a £Òesearch: Good Clinical Practice in Clinical Trials£ÛJ£Ý£®Clinical Trials£¬2013£¬3(1): 128-132£®

[3] ICH. Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies [EB/OL].(1994-10-27)

[4] ¹ú¼ÒʳƷҩƷ¼à¶½¹ÜÀí×ܾÖÒ©Æ·ÉóÆÀÖÐÐÄ.¹ØÓÚÔÚÐÂÒ©·ÇÁÙ´²Ñо¿ÆÀ¼ÛÖвο¼Ê¹ÓÃICH M3 Ö¸µ¼Ô­ÔòµÄר¼Ò¹²Ê¶Òâ¼û.(2016-08-05)

[5] Ñºì,º«Åô,ÕÅÑåÑå,µÈ.ÎÒ¹úʵʩ ICH SϵÁм¼ ÊõÖ¸µ¼Ô­ÔòµÄ²ßÂÔÑо¿ [J]. ÏÖ´úÒ©ÎïÓëÁÙ´², 2018, 33(7): 1843-1847.

[6] ³ÂÕð,ºúÝí,Ñºì,µÈ.ÎÒ¹úʵʩICH EϵÁм¼ÊõÖ¸µ¼Ô­ÔòµÄ²ßÂÔÑо¿ [J]. ÏÖ´úÒ©ÎïÓëÁÙ´², 2018,33(9): 2455-2460.

ÁªÏµ¿Í·þ£º779662525#qq.com(#Ìæ»»Îª@) ËÕICP±¸20003344ºÅ-4